Literature DB >> 2060252

Kinetics of D-xylose absorption in patients with human immunodeficiency virus enteropathy.

E D Ehrenpreis1, S P Gulino, B K Patterson, R M Craig, H Yokoo, A J Atkinson.   

Abstract

D-Xylose absorption was studied in 12 patients with acquired immunodeficiency syndrome (AIDS) or advanced AIDS-related complex who had had diarrhea for more than 8 weeks, averaged an 11% (range, 3% to 21%) body weight loss during the previous 6 months, and had had negative stool examinations for enteric pathogens. Patients were evaluated by duodenal aspiration and biopsy and received both 25 gm oral and 10 gm intravenous doses of D-xylose. Kinetic analysis of D-xylose absorption was characterized by an absorption rate constant (ka) and a rate constant (ko) reflecting nonabsorptive loss. Extent of D-xylose absorption averaged 18.4% +/- 9.3% (+/- SD) in the 12 patients (normal greater than 60%). Percentage of weight loss during the previous 6 months was negatively correlated with ka (r = -0.69; p = 0.018) in the 11 patients in whom this parameter was reduced but was not correlated with either ko or extent of D-xylose absorption. In these patients with human immunodeficiency virus enteropathy, ka was reduced out of proportion to the minor histologic changes present in the duodenal biopsy specimens.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060252     DOI: 10.1038/clpt.1991.80

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  10 in total

1.  Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome.

Authors:  G Gatti; A Di Biagio; C R De Pascalis; M Guerra; M Bassetti; D Bassetti
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

2.  Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.

Authors:  R C Owens; K B Patel; M A Banevicius; R Quintiliani; C H Nightingale; D P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

3.  Oral bioavailability and pharmacokinetics of trovafloxacin in patients with AIDS.

Authors:  M K Lacy; D P Nicolau; C H Nightingale; A Geffken; R Teng; J Vincent; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Gp120-induced Bob/GPR15 activation: a possible cause of human immunodeficiency virus enteropathy.

Authors:  F Clayton; D P Kotler; S K Kuwada; T Morgan; C Stepan; J Kuang; J Le; J Fantini
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

Review 5.  Clinical pharmacokinetics of zidovudine. An update.

Authors:  E P Acosta; L M Page; C V Fletcher
Journal:  Clin Pharmacokinet       Date:  1996-04       Impact factor: 6.447

6.  Urinary recovery of lactulose compared to D-xylose absorption kinetics in HIV patients with diarrhea and weight loss.

Authors:  S J Carlson; C Webster; R M Craig
Journal:  Dig Dis Sci       Date:  1997-12       Impact factor: 3.199

7.  Malabsorption and deficiency of vitamin B12 in HIV-infected patients with chronic diarrhea.

Authors:  E D Ehrenpreis; S J Carlson; H L Boorstein; R M Craig
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

8.  Intestinal absorptive capacity, intestinal permeability and jejunal histology in HIV and their relation to diarrhoea.

Authors:  J Keating; I Bjarnason; S Somasundaram; A Macpherson; N Francis; A B Price; D Sharpstone; J Smithson; I S Menzies; B G Gazzard
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

9.  D-xylose hydrogen breath tests compared to absorption kinetics in human patients with and without malabsorption.

Authors:  S Carlson; R M Craig
Journal:  Dig Dis Sci       Date:  1995-10       Impact factor: 3.199

10.  Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS.

Authors:  G Gatti; J Flaherty; J Bubp; J White; M Borin; J Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.